Fresenius Medical’s (FMS) heart and lung group has been awarded a national group purchasing agreement for Mechanical Circulatory Support with Premier in the U.S. Since acquiring Xenios in 2016, Fresenius has been dedicated to advancing heart and lung therapy. The Novalung System for extracorporeal membrane oxygenation – ECMO -, was the first system FDA-cleared for long-term ECMO. The system pumps and oxygenates the blood of patients with acute respiratory failure or acute cardiopulmonary failure. Novalung offers a portable therapy solution designed to improve clinical outcomes and accommodate various clinical care settings. Premier is a healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target raised to EUR 39 from EUR 38.50 at Barclays
- Fresenius Medical price target raised to EUR 37.30 from EUR 35.40 at JPMorgan
- Fresenius Medical ADRs initiated with a Buy at Berenberg
- Fresenius Medical Care Reports Strong Q3 2024 Results
- Fresenius Medical Care Unveils New Long-Term Incentive Plan